Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.57 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389346 | 0.94 | HTR7 (0.55) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL3389898 | 0.93 | HTR7 (0.54) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL3388018 | 0.92 | HTR7 (0.53) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL4995479 | 0.92 | HTR7 (0.53) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL3388255 | 0.92 | HTR7 (0.53) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL3390269 | 0.86 | ABCB1 (0.56) | HRH3HTR7CNR2L3MBTL3L3MBTL1 | |
| SCHEMBL3388617 | 0.85 | DRD2 (0.52) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL3388040 | 0.84 | DRD2 (0.49) | HRH3HTR7L3MBTL3L3MBTL1ABCB1 | |
| SCHEMBL3391314 | 0.83 | OXTR (0.52) | HRH3CNR2L3MBTL3L3MBTL1 | |
| SCHEMBL3390563 | 0.81 | OXTR (0.47) | HRH3CNR2L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2029534-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2007131907-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HRH4, HRH2, HRH3 | HRH3 3/4885HTR7 12/4885CNR2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.